

Fracture Liaison Service Database (FLS-DB)

Case study: Improving KPI 10 – Treatment by first appointment and KPI 11 1 year drug adherence

Haywood Hospital/Midland Metabolic Bone Centre Midland Partnership University NHS Foundation Trust Prof Zoe Paskins

Background

Denosumab was previously being given in daycase in the rheumatology hospital by non-specialist nurses and incurring a daycase tariff for commissioners.

Outpatient clinic had over a year waiting list for follow up appointments for patients on injectable treatment meaning clinical reviews were delayed on these patients N = 400 patients

Aim

- 1. Improve patient experience, giving the drug closer to people's home and by a specialist nurse who could also undertake a specialist review
- 2. Reduce costs associated with daycase tariff
- 3. Reduce demand on medical outpatients

Process

We set up an improvement team made up of the FLS lead, consultant, FLS nurse, DXA radiographers and 2 patients and operational manager.

We discussed this priority in our monthly multidisciplinary team meeting to identify potential solutions, and iterative service developments.

Interventions:

- Appointed a Band 6 nurse to solely take over management of denosumab, including monitoring, administering, and increasing range of locations the drug could be given at closer to people's homes
- The appointed nurse underwent training, including attending medical clinics, to undertake clinical reviews every 3 years, including screen for new vertebral fractures, consideration of monitoring, falls assessment, meaning that patients only come to medical clinic if they need a medical review of treatment
- 3. A standard operating procedure was developed to support reviews
- 4. Medical oversight included set up of a weekly consultant led-MDT for drug related queries.
- 5. Processes set up to support prescribing of the drug and any additional vitamin D replacement needed.



Fracture Liaison Service Database (FLS-DB)

Outcomes

Patient satisfaction

User and Carer Experience Survey – Denosumab Sept 2021

- N=20
- 100% extremely satisfied
- 100% would definitely recommend to friends and family

Comments include 'Convenient and personal', 'closer to home, friendly staff'

<u>Clinical outcomes</u> – adherence is high

Denosumab adherence audit 2021

- 90% receive injection within 4 weeks
- 96% within 8 weeks

Waiting list for medical clinic reduced from 400 to 0 (although other factors contributed to this). Patients have less travel, have their osteoporosis information needs met, patient safety is improved

What did you learn?

- 1. Day case tariff was driver to improve patient care.
- 2. Quality improvement likely reduced costs and improved patient experience.
- 3. Patients on injectable therapy need minimal medic input.
- 4. Adherence/persistence to denosumab given by a community nurse affiliated to a specialist centre is much better than that seen in primary care.